JP2022512713A5 - - Google Patents
Info
- Publication number
- JP2022512713A5 JP2022512713A5 JP2021520958A JP2021520958A JP2022512713A5 JP 2022512713 A5 JP2022512713 A5 JP 2022512713A5 JP 2021520958 A JP2021520958 A JP 2021520958A JP 2021520958 A JP2021520958 A JP 2021520958A JP 2022512713 A5 JP2022512713 A5 JP 2022512713A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024108735A JP2024138363A (ja) | 2018-10-16 | 2024-07-05 | 重症筋無力症の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746174P | 2018-10-16 | 2018-10-16 | |
| US62/746,174 | 2018-10-16 | ||
| PCT/EP2019/078093 WO2020079086A1 (en) | 2018-10-16 | 2019-10-16 | Method for the treatment of myasthenia gravis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108735A Division JP2024138363A (ja) | 2018-10-16 | 2024-07-05 | 重症筋無力症の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512713A JP2022512713A (ja) | 2022-02-07 |
| JP2022512713A5 true JP2022512713A5 (cg-RX-API-DMAC7.html) | 2022-10-24 |
| JP7518821B2 JP7518821B2 (ja) | 2024-07-18 |
Family
ID=68290236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520958A Active JP7518821B2 (ja) | 2018-10-16 | 2019-10-16 | 重症筋無力症の治療方法 |
| JP2024108735A Pending JP2024138363A (ja) | 2018-10-16 | 2024-07-05 | 重症筋無力症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108735A Pending JP2024138363A (ja) | 2018-10-16 | 2024-07-05 | 重症筋無力症の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220144941A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3866933A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7518821B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102916165B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113646051A (cg-RX-API-DMAC7.html) |
| AR (1) | AR117653A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019361247B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021007092A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3116091A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282137A (cg-RX-API-DMAC7.html) |
| MA (1) | MA53903A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004351A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103801UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020079086A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| CA3200972A1 (en) * | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| CN116782939A (zh) * | 2020-11-06 | 2023-09-19 | 动量制药公司 | FcRn抗体及其使用方法 |
| MX2023012032A (es) * | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| CN119013290A (zh) | 2022-04-13 | 2024-11-22 | Ose免疫疗法公司 | 用于选择性清除抗体的新型分子 |
| EP4519683A1 (en) * | 2022-05-05 | 2025-03-12 | UCB Biopharma SRL | Treatment of myasthenia gravis with zilucoplan |
| JP2025519559A (ja) * | 2022-06-11 | 2025-06-26 | インヒブルクス バイオサイエンシズ インコーポレイテッド | FcRn結合ポリペプチド及びその使用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| WO2004051268A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| JP2008538919A (ja) | 2005-04-29 | 2008-11-13 | ザ ジャクソン ラボラトリー | FcRn抗体およびその使用 |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US8273351B2 (en) | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| EP2453823B1 (en) | 2009-07-14 | 2015-05-13 | WaveTec Vision Systems, Inc. | Ophthalmic surgery measurement system |
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201320066D0 (en) * | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| EP4241852A3 (en) | 2014-04-30 | 2023-11-15 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| MA51032A (fr) * | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
-
2019
- 2019-10-16 JP JP2021520958A patent/JP7518821B2/ja active Active
- 2019-10-16 KR KR1020217014478A patent/KR102916165B1/ko active Active
- 2019-10-16 WO PCT/EP2019/078093 patent/WO2020079086A1/en not_active Ceased
- 2019-10-16 CA CA3116091A patent/CA3116091A1/en active Pending
- 2019-10-16 SG SG11202103801UA patent/SG11202103801UA/en unknown
- 2019-10-16 MX MX2021004351A patent/MX2021004351A/es unknown
- 2019-10-16 AR ARP190102931A patent/AR117653A1/es unknown
- 2019-10-16 MA MA053903A patent/MA53903A/fr unknown
- 2019-10-16 CN CN201980077400.3A patent/CN113646051A/zh active Pending
- 2019-10-16 BR BR112021007092-3A patent/BR112021007092A2/pt not_active Application Discontinuation
- 2019-10-16 AU AU2019361247A patent/AU2019361247B2/en active Active
- 2019-10-16 KR KR1020267001580A patent/KR20260014044A/ko active Pending
- 2019-10-16 US US17/286,247 patent/US20220144941A1/en active Pending
- 2019-10-16 EP EP19790182.0A patent/EP3866933A1/en active Pending
-
2021
- 2021-04-07 IL IL282137A patent/IL282137A/en unknown
-
2024
- 2024-07-05 JP JP2024108735A patent/JP2024138363A/ja active Pending